Evidence map›Paper›PMID 28384010›Full record

Trial reportJournal of child and adolescent psychopharmacology2017

Placebo Response in Pediatric Anxiety Disorders: Results from the Child/Adolescent Anxiety Multimodal Study.

Jeffrey R Strawn, Eric T Dobson, Jeffrey A Mills, Gary J Cornwall, Dara Sakolsky, Boris Birmaher, Scott N Compton, John Piacentini, James T McCracken, Golda S Ginsburg and 4 more

Registry-linked trialOpen access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of child and adolescent psychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04598230 (Partners in Caring for Anxious Youth), which is not on this map. Cited by 21 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 4 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04598230 phase3active not recruitingnot on this mapstarted 2021, after this paper: background citation

Partners in Caring for Anxious Youth

TypeinterventionalSponsorAnn & Robert H Lurie Children's Hospital of ChicagoRan2021 to 2026Enrolled468ConditionsAnxiety, Separation, Anxiety, Generalized, Anxiety, SocialArmsCognitive Behavioral Therapy (CBT), Combination therapy (COMB)
3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 34 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Acute neurofunctional effects of escitalopram during emotional processing in pediatric anxiety: a double-blind, placebo-controlled trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022
    Trial
  7. Acute Neurofunctional Effects of Escitalopram in Pediatric Anxiety: A Double-Blind, Placebo-Controlled Trial.Journal of the American Academy of Child and Adolescent Psychiatry · 2021
    Trial
  8. Trial
  9. Trial
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Pediatric Psychopharmacology for Depressive and Anxiety Disorders.Focus (American Psychiatric Publishing) · 2022
    Review
  16. Research Review: Pediatric anxiety disorders - what have we learnt in the last 10 years?Journal of child psychology and psychiatry, and allied disciplines · 2021
    Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 1 country.

Jeffrey R Strawn1 Department of Psychiatry and Behavioral Neuroscience, College of Medicine, University of Cincinnati , Cincinnati, Ohio.
Eric T Dobson1 Department of Psychiatry and Behavioral Neuroscience, College of Medicine, University of Cincinnati , Cincinnati, Ohio.
Jeffrey A Mills3 Carl H. Lindner College of Business, University of Cincinnati , Cincinnati, Ohio.
Gary J Cornwall3 Carl H. Lindner College of Business, University of Cincinnati , Cincinnati, Ohio.
Dara Sakolsky4 Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center , Pittsburgh, Pennsylvania.
Boris Birmaher4 Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center , Pittsburgh, Pennsylvania.
Scott N Compton5 Duke University Medical Center , Durham, North Carolina.
John Piacentini6 Semel Institute for Neuroscience and Human Behavior, University of California , Los Angeles (UCLA), Los Angeles, California.
James T McCracken6 Semel Institute for Neuroscience and Human Behavior, University of California , Los Angeles (UCLA), Los Angeles, California.
Golda S Ginsburg7 University of Connecticut Health Center , West Hartford, Connecticut.
Phillip C Kendall8 Temple University , Philadelphia, Pennsylvania.
John T Walkup9 Weill Cornell Medical College and New York Presbyterian Hospital , New York, New York.
Anne Marie Albano10 Columbia University Medical Center (CUMC)/New York State Psychiatric Institute , New York, New York.
Moira A Rynn10 Columbia University Medical Center (CUMC)/New York State Psychiatric Institute , New York, New York.
University of Cincinnati Medical Center · USUniversity of Pittsburgh Medical Center · USCincinnati Children's Hospital Medical Center · USDuke Medical Center · USNewYork–Presbyterian Hospital · USTemple University · USUConn Health · US

Funding

Neurofunctional Predictors of Treatment Response in Adolescents with GADK23MH106037 · NIMH · UNIVERSITY OF CINCINNATI · PI STRAWN, JEFFREY ROBERT · 2014 to 2017
$745k
NIMH NIH HHS K23 MH106037
6 · The paper itself

Abstract

objectivesThe aim of this study is to identify predictors of pill placebo response and to characterize the temporal course of pill placebo response in anxious youth.

methodsData from placebo-treated patients (N = 76) in the Child/Adolescent Anxiety Multimodal Study (CAMS), a multisite, randomized controlled trial that examined the efficacy of cognitive-behavioral therapy, sertraline, their combination, and placebo for the treatment of separation, generalized, and social anxiety disorders, were evaluated. Multiple linear regression models identified features associated with placebo response and models were confirmed with leave-one-out cross-validation. The likelihood of improvement in patients receiving pill placebo-over time-relative to improvement associated with active treatment was determined using probabilistic Bayesian analyses.

resultsBased on a categorical definition of response (Clinical Global Impressions-Improvement Scale score ≤2), nonresponders (n = 48), and pill placebo responders (n = 18) did not differ in age (p = 0.217), sex (p = 0.980), race (p = 0.743), or primary diagnosis (all ps > 0.659). In terms of change in anxiety symptoms, separation anxiety disorder and treatment expectation were associated with the degree of pill placebo response. Greater probability of placebo-related anxiety symptom improvement was observed early in the course of treatment (baseline to week 4, p < 0.0001). No significant change in the probability of placebo-related improvement was observed after week 4 (weeks 4-8, p = 0.07; weeks 8-12, p = 0.85), whereas the probability of improvement, in general, significantly increased week over week with active treatment.

conclusionsPill placebo-related improvement occurs early in the course of treatment and both clinical factors and expectation predict this improvement. Additionally, probabilistic approaches may refine our understanding and prediction of pill placebo response.

Indexed as

Placebo EffectAdolescentAnxiety DisordersBayes TheoremChildCognitive Behavioral TherapyCombined Modality TherapyFemaleHumansMaleSelective Serotonin Reuptake InhibitorsSertralineSelective Serotonin Reuptake InhibitorsSertralineantidepressantanxietyBayesianclinical trialresponse

Identifiers

PMID28384010
PMCPMC5568015
OpenAlexW2606531459

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.